The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA‐Q)

Abstract

Introduction The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA‐Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia. Methods CIMA‐Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community. Results In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a 18fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture. Discussion CIMA‐Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease.

A quadratic function of activation in individuals at risk of Alzheimer's disease

“…The study included data from the Consortium for the Early Identification of Alzheimer's disease‐Quebec cohort (CIMA‐Q http://www.cima-q.ca/en/home/). 16 The main objective of CIMA‐Q is to characterize a longitudinal observational cohort consisting of more than 350 community‐dwelling older adults recruited via advertisements, electronic media, and memory clinics from three Canadian cities (Montreal, Sherbrooke, and Quebec City). Participants were either: (1) cognitively healthy, (2) exhibiting SCD, (3) suffering from MCI, or (4) diagnosed with dementia due to probable AD.…”

Effects of Computerized Updating and Inhibition Training in Older Adults: The ACTOP Three-Arm Randomized Double-Blind Controlled Trial

“…We first analyzed demographic information (age, sex, education) and baseline characterization from the cognitive reserve proxy questionnaire (CRQ) ( 31 ), ischemic index ( 32 ) and depression questionnaires [short version of Geriatric depression scale (GDS) for older adults ( 33 ) and Beck Depression Inventory II (BDI-II) for young adults]. Cognition was measured with the Montreal Cognitive Assessment (MoCA) ( 34 ) and a French version of the logical memory subtest (CIMAQ) ( 35 ) adapted from the Wechsler Memory Scale ( 36 ) using separated one-way ANOVAs with Group (three levels) as a between-subject factor.…”

Neural correlates of resilience to the effects of hippocampal atrophy on memory

“…Participants included 108 older adults from the Quebec Consortium for the early identification of Alzheimer’s disease (CIMA-Q). CIMA-Q is a multi-center collaborative research infrastructure that tracks AD progression in older adults at risk for the disease ( Belleville et al, 2019 ). The consortium has created a longitudinal cohort of older adults meeting criteria for SCD, MCI, dementia of the Alzheimer’s type (AD), and healthy controls (HC).…”

“…The study included 25 older adults with MCI, 58 older adults with SCD and 25 HC, all of whom completed the clinical, neuropsychological, and fMRI examination ( Table 1 ). All procedures of recruitment, clinical, cognitive, neuropsychiatric measures are described in Belleville et al, 2014 , Belleville et al, 2019 and can be found in Supplementary Material (S1 text) . The CIMA-Q study and this present study were approved by the Research Ethics Board of the Institut universitaire de gériatrie de Montréal.…”

“…CIMA-Q uses a comprehensive imaging protocol harmonized for manufacturers/software configurations to optimize commonality ( Belleville et al, 2019 , Duchesne et al, 2019 ). This present study uses anatomical 3D-T 1 -w and task-related fMRI sequences from this protocol ( cf .…”